Use of 2-substituted indazoles for the treatment and prophylaxis of autoimmune diseases

US11992481B2 · kind B2 · utility

Assignee

• Bayer Pharma Aktiengesellschaft · DE

Inventors

• Alexandra RAUSCH · Berlin, DE
• Stefan Joachim JODL · Kleinmachnow, DE
• Jörn KRÄTZSCHMAR · Berlin, DE
• Ulrich Bothe · Berlin, DE
• Nicole SCHMIDT · San Francisco, US

Key dates

• Filing date: Feb 16, 2022
• Grant date: May 28, 2024
• Expiry date: Feb 16, 2042

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P37/06
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present application relates to substituted indazoles, to the use thereof alone or in combinations for treatment and/or prophylaxis of autoimmune disorders, and to the use thereof for production of medicaments for treatment and/or prophylaxis of autoimmune disorders, especially for treatment and/or prophylaxis of arthritides (especially psoriatic arthritis, rheumatoid arthritis, Bekhterev's disease, reactive arthritis, systematic juvenile idiopathic arthritis), systematic lupus erythematosus, multiple sclerosis, psoriasis, atopic dermatitis, allergic eczema and chronic-inflammatory bowel disorders (especially Crohn's disease and ulcerative colitis).